Alpha-GPC
Also known as: L-Alpha glycerylphosphorylcholine, Choline alfoscerate, sn-glycero-3-phosphocholine, L-alpha-Glycerophosphorylcholine
Lower numbers = closer to natural. Higher numbers = more enhanced.
Why this rating?
Alpha-GPC is a choline source / acetylcholine precursor used as a cognitive supplement and, in some countries, a prescription drug for dementia. It is not a hormone, does not build muscle and is not on the WADA list; the once-touted acute growth-hormone bump did not replicate in a 2024 randomized, placebo-controlled crossover, which found no GH or physical-performance effect despite improved cognition. As a nootropic/cholinergic supplement with no credible path to raising anabolic hormones, building muscle or burning fat, alpha-GPC is rated 1 (basically natty - no meaningful effect on the muscular/physique scale).
Overview
A natural choline compound found in the brain that acts as an acetylcholine precursor. Alpha-GPC rapidly delivers choline across the blood-brain barrier, where it is used to make acetylcholine. It is sold as a nootropic/pre-workout supplement and, in several countries, prescribed as choline alfoscerate for cognitive decline.
Purpose & Use Cases
Cognitive Support
Used to support memory and cognition. A 2023 meta-analysis found alpha-GPC improved cognitive function and daily living in dementia of neurological origin, vascular dementia and Alzheimer's disease; an acute RCT in healthy men improved a cognitive (Stroop) test.
Choline Source for Nootropic Stacks
A go-to choline donor stacked with racetams (e.g. phenylpiracetam) and other nootropics to supply acetylcholine and blunt racetam 'choline headaches'.
Pre-Workout / Possible Acute GH Bump
Popular in pre-workouts. An older study reported alpha-GPC augments the growth-hormone response to GHRH - but see the honest evidence flags: a 2024 exercise RCT found no GH or physical-performance effect.
Benefits
- Effective, bioavailable choline source that crosses the blood-brain barrier
- Meta-analysis support for cognition in dementia populations
- Acute cognitive (Stroop) improvement shown in healthy men
- Pairs with racetams to reduce choline-depletion headaches
- Generally well tolerated; FDA GRAS at up to ~196mg/day
Good to Know
A choline delivery system for the brain
Alpha-GPC crosses the blood-brain barrier and feeds acetylcholine synthesis. That is why it supports cognition and why it is paired with racetams - the racetam raises acetylcholine use and alpha-GPC supplies the raw material, reducing the classic racetam headache.
The GH and 'power output' claims are weak/mixed - be honest
An older study (Ceda 1992) found alpha-GPC increased the GH response to GHRH, which is the origin of the 'raises growth hormone' reputation. But a 2024 randomised, placebo-controlled crossover in healthy trained men found NO effect on growth hormone or on physical performance (vertical jump, bench-press throws) despite improving cognition. So treat the acute-GH and power-output benefits as unproven for real-world training.
A large study flagged a stroke-risk association
A South Korean retrospective cohort of roughly 12 million people (Lee et al. 2021, JAMA Network Open) reported a 46% higher 10-year stroke risk in alpha-GPC users, with a dose-response pattern. This is an association from observational data (confounding/indication bias is likely), not established cause and effect - a later 2025 nationwide study in patients with mild cognitive impairment found the opposite direction (lower stroke risk), underlining how mixed and population-dependent this signal is. Still, it is the single most important safety caveat and worth weighing before chronic high-dose use.
Dosage Guidelines
| Experience Level | Dosage Range |
|---|---|
| Beginner | 300 – 315 mg/day |
| Intermediate | 315 – 600 mg/day |
| Advanced | 600 – 630 mg/day |
The 2024 RCT (Kerksick) used 315mg (low) and 630mg (high) acutely - the high dose improved cognition. Common nootropic/pre-workout practice is 300-600mg/day (community-derived, e.g. Examine.com and nootropic-vendor guidance), while the therapeutic dose used in dementia trials is much higher, up to 1200mg/day split into 2-3 doses (e.g. Moreno 2003, 261 Alzheimer's patients, 1200mg/day for 180 days). The FDA GRAS ceiling is ~196.2mg/person/day for use as a food ingredient (GRN 419), which is below common supplement doses - that ceiling applies to food fortification, not supplement dosing. No RCT establishes an optimal chronic cycle length; the 4-12 week range and periodic breaks reflect common community practice rather than clinical evidence, since long-term dementia trials instead run continuously for months.
Plasma choline peaks ~30-60min post-dose; the elimination half-life is not rigorously established in humans (very limited PK data, roughly 4-8h apparent in small studies).
Side Effects
Headache
uncommonOccasional headache with cholinergic supplements.
Lower dose.
GI Upset / Heartburn
uncommonMild digestive discomfort.
Take with food.
Possible Stroke-Risk Association
rareA large South Korean retrospective cohort (~12 million participants) found alpha-GPC users had a 46% higher risk of stroke. This is an observational association, not proven causation, but it is a genuine flag worth weighing for long-term/high-dose use.
Discuss with a physician if you have cardiovascular/stroke risk factors; avoid unnecessary chronic high-dose use.
General Mitigation Strategies
Alpha-GPC is generally well tolerated. The main non-trivial concern is the observational stroke-risk association from a large Korean cohort - association only, but a reason not to megadose chronically without cause, especially with cardiovascular risk factors.
Post Cycle Therapy (PCT)
Not a hormone and does not affect the HPTA. No PCT required.
How It Works
Alpha-GPC is a parasympathomimetic acetylcholine precursor: it crosses the blood-brain barrier and serves as a biosynthetic precursor of acetylcholine, raising central cholinergic tone. This is the basis of its use for cognition and its pairing with racetams (which increase acetylcholine turnover).
Fundamentals
Reference on the practices relevant to Alpha-GPC: how they are done and where they go wrong. Not a recommendation to use it.
Legal Status
Non-prescription supplement in most countries (USA: FDA GRAS at <=196.2mg/day); prescription drug (choline alfoscerate) for dementia in some countries.
Legal status varies by country and changes over time. This is a general summary, not legal advice.
WADA Status
Alpha-GPC is a choline-containing dietary supplement and is not listed on the WADA Prohibited List. It is neither a hormone nor a stimulant.
References
- Alpha-GPC - Wikipedia
- Ceda et al. 1992 - alpha-GPC increases GH response to GHRH (PMID 1577400)
- Kerksick 2024 - acute alpha-GPC RCT: cognition up, no GH/performance effect (PMID 39683633)
- Lee et al. 2021, JAMA Network Open - alpha-GPC and 10-year stroke risk in ~12M Korean adults (46% higher total-stroke HR)
- Sagaro, Traini & Amenta 2023 - Choline alphoscerate meta-analysis in adult-onset cognitive dysfunction (J Alzheimers Dis)
- FDA GRAS Notice GRN 419 - Alpha-GPC as a choline source, 196.2mg/person/day 90th-percentile intake